Very low lipoprotein(a) and type 2 diabetes: implications for ongoing clinical trials
American Journal of Preventive Cardiology · 2027-01 · 31 · 101793
DOI: 10.1016/j.ajpc.2026.101793 ↗Kurz gefasst
Editorial in der Zeitschrift American Journal of Preventive Cardiology, 2027-01. Verfasst von Izza Shahid und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Prevention and Wellness, DeBakey Heart and Vascular Center, Houston, TX, USA. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
early version to give early visibility of the article.
Autor:innen und Institutionen
- Division of Cardiovascular Prevention and Wellness, DeBakey Heart and Vascular Center, Houston, TX, USA.
- Center for Cardiovascular Computational and Precision Health (C3PH), Houston Methodist, Houston, TX, USA.
- University of California San Diego Health, La Jolla, CA, USA.
Zitieren
APA
Shahid, I., & Bhatia, H. S. (2027). Very low lipoprotein(a) and type 2 diabetes: implications for ongoing clinical trials. American Journal of Preventive Cardiology, 31, 101793. https://doi.org/10.1016/j.ajpc.2026.101793
Vancouver
Shahid I, Bhatia HS. Very low lipoprotein(a) and type 2 diabetes: implications for ongoing clinical trials. American Journal of Preventive Cardiology. 2027;31:101793. doi:10.1016/j.ajpc.2026.101793
BibTeX
@article{Shahid2027,
author = {Shahid, Izza and Bhatia, Harpreet S},
title = {Very low lipoprotein(a) and type 2 diabetes: implications for ongoing clinical trials},
journal = {American Journal of Preventive Cardiology},
year = {2027},
volume = {31},
pages = {101793},
doi = {10.1016/j.ajpc.2026.101793}
}
EUVIMED